Mersana Therapeutics Inc (NAS:MRSN)
$ 2.37 0.07 (3.04%) Market Cap: 292.77 Mil Enterprise Value: 160.46 Mil PE Ratio: 0 PB Ratio: 237.00 GF Score: 29/100

Mersana Therapeutics Inc at Cowen Oncology Innovation Summit: Insights for ASCO & EHA (Virtual) Transcript

Jun 02, 2022 / 05:00PM GMT
Release Date Price: $3.22 (+0.31%)
Boris Peaker
Cowen and Company, LLC - Analyst

Thank you for joining us at the Third Annual Cowen Oncology Innovation Summit. And the next company with us is Mersana Therapeutics. And it's my pleasure to host, Brian DeSchuytner, who is the Senior Vice President and Chief Financial Officer; and Tim Lowinger, who is the Chief Science and Technology Officer. Thanks, guys, for joining us today.

Brian DeSchuytner
Mersana Therapeutics, Inc. - SVP & CFO

Great. Thank you, Boris. Maybe we'll make a quick opening statement to give an overview of Mersana. I'll begin and I'll make some forward-looking statements in the process of that.

So Mersana is a leader in ADC innovation. Our strategic vision is to build on this leadership from discovery to commercialization. ADCs are now validated modality, yet we believe that the field has yet to realize its full potential because the platform innovation has been limited to date. We've actually developed three proprietary platforms that we believe address key limitations of the first-generation approaches and at the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot